Transgene Biotek Limited is in the business of Research & Development of Pharmaceutical products. The registered office of the company is in Telangana.Business Expertise: Company is in production and oral formulation of different proteins using TrabiORAL technology a) Oncology b) Auto Immunity c) Drug Delivery d) Biogenerics
Transgene Biotek Limited has released its unaudited financial results for the quarter ending June 30, 2025. The company's total income from operations for the quarter was 25.95, with a net profit after tax of 1.94. Equity share capital stood at 649.02, and earnings per share were 0.03. These figures offer...
Transgene Biotek Limited has clarified that it is not required to submit a Statement of Deviation or Variation for fund utilization. This is because the company did not raise capital through public, rights, or preferential issues during the recent quarter. Essentially, there were no new shares issued via these specific...
Transgene Biotek has confirmed, via its share transfer agent, that no physical shares were converted to electronic form (dematerialized) or vice-versa (rematerialized) during the quarter from April 1 to June 30. This update is part of routine compliance, ensuring transparent and accurate records of investor shareholdings. It signifies a stable...
Transgene Biotek Limited has announced a board meeting to consider the financial results for the quarter and half-year. Canara Bank’s Khairatabad Branch has initiated an e-auction of immovable property mortgaged by M/s Lotus Poly-Packs (India) Pvt Ltd due to a loan default of Rs. 4.32 Cr plus interest. The reserve...
Transgene Biotek Limited has submitted a Compliance Certificate for the quarter ended 31st March 2025, confirming that, during the reporting period, no shares were received for transfer, sub-division, consolidation, renewal, exchange, or endorsement of calls/allotment monies. This reflects a stable status regarding equity share transactions, which may indicate operational consistency....
